The management seems great. Paul Hopper has managed to recruit a management who is I believe responsible for 4 of the 5 total approved CAR-T therapies. Seems to be a best in class management and it says a lot that these folk were keen to join this Australian biotech, I think the results are very encouraging so far as expected, as they probably saw promise in these assets. There are plenty of presentations on youtube too from Jennifer Chow.
The pipeline has rapidly expanded too. @stockrock has some awesome analysis in earlier threads explaining how the CORE-NK platform is differentiated. And the main ongoing Phase 1 trial against glioblastoma has had promising results so far. They have completed 2 of the 4 total dose cohorts now, with no adverse effects, and high rates of disease stability.
This one is earlier than other biotechs we are in, so I'm not sure how much will happen before 2023-24. For me in the shorter term I am keen to see what happens with the other two dose cohorts in the glioblastoma trial. Dose 3 is almost 3x the dosage as dose 2. Potentially we may start to see some clues re efficacy as this dosage is upped, considering we are seeing disease stability at a lower dose.
CHM Price at posting:
16.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)